Multiple focal atrial tachycardia as a characteristic finding of intractable arrhythmia associated with wild-type transthyretin amyloid cardiomyopathy

Hisanori Kanazawa, MD, PhD,* Miwa Ito, MD, PhD,* Yusei Kawahara, MD,* Tadashi Hoshiyama, MD, PhD,* Seiji Takashio, MD, PhD,* Kenichi Tsujita, MD, PhD*

From the *Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan, and †Department of Cardiac Arrhythmias, Kumamoto University, Kumamoto, Japan.

Introduction
Wild-type transthyretin amyloid cardiomyopathy (ATTRw~t-CM) is a secondary cardiomyopathy with cardiac hypertrophy. An increasing number of patients with ATTRw~t-CM can be diagnosed by various detailed examinations, such as cardiac magnetic resonance imaging (MRI), technetium-99m-labeled pyrophosphate (99mTc-PYP) scintigraphy, and histopathological evidence of amyloid deposition in the tissue, including the abdominal fat or upper gastrointestinal mucosa. In our institution, 129 patients were diagnosed with ATTRw~t-CM between December 2002 and December 2019, and we have previously reported the clinical features and prognosis of patients with ATTRw~t-CM in the largest number of cases in Japan.1

On the other hand, atrial fibrillation (AF), atrial flutter, and atrial tachycardia (AT) are more frequently observed in patients with ATTRw~t-CM,2–5 with increasing opportunities for catheter ablation. Under these circumstances, we encountered several cases of ATTRw~t-CM with multiple focal AT episodes that were extremely difficult to treat.

Although a larger case series of all amyloid subtypes undergoing various atrial arrhythmia ablations has been published,6 individual case details of multiple focal AT episodes associated with ATTRw~t-CM have not been previously published. Therefore, we report a representative case of multiple focal AT episodes, a characteristic finding of patients with ATTRw~t-CM. Written informed consent was obtained from the patient.

KEY TEACHING POINTS
- Multiple focal atrial tachycardia (AT) is a characteristic finding of wild-type transthyretin amyloid cardiomyopathy (ATTRw~t-CM); to our knowledge, this is the first case report on the details of intractable multiple focal AT episodes associated with ATTRw~t-CM.
- Especially in elderly patients with ATTRw~t-CM, the scar area is widely spread, and multiple focal microreentrant AT episodes are likely to occur in the amyloid-deposited atrium.
- Although multiple focal AT episodes persist, they are readily stopped by catheter contact with the atrial wall during mapping. In contrast, they are not terminated easily by radiofrequency energy application, suggesting that multiple focal AT is fragile but relentless.
- It is difficult to cure multiple focal AT episodes completely because they continue to be induced regardless of the number of radiofrequency energy applications delivered. Therefore, atrioventricular node ablation is a reasonable treatment instead of directly targeting multiple focal AT.

KEYWORDS Wild-type transthyretin amyloid cardiomyopathy; Atrial tachycardia; Multiple focal atrial tachycardia; Catheter ablation; Atrioventricular node ablation

(Heart Rhythm Case Reports 2022;8:420–424)

Funding Sources: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Disclosures: Dr Kanazawa has received grants from Medtronic Japan, Nihon Kohden, Abbott Medical Japan, Fukuda Denki, Boston Scientific Japan, Japan Lifeline, Nipro, and Biotronik Japan. Dr Tsujita has received honoraria from Bayer Yakuhin, Daiichi-Sankyo, Kowa, MSD, Sanofi, and Takeda Pharmaceutical, and grants from Astellas Pharma, Abbott Vascular Japan, Bayer Yakuhin, Boehringer Ingelheim Japan, Boston Scientific Japan, Bristol-Myers, Chugai Pharmaceutical, Daiichi-Sankyo, Goodman, Japan Lifeline, Medtronic Japan, Mitsubishi Tanabe Pharma, MSD, Novartis Pharma, Otsuka Pharmaceutical, Sanofi, Takeda Pharmaceutical, and Terumo. All other authors declare no conflicts of interest. Address reprint requests and correspondence: Dr Hisanori Kanazawa, Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan. E-mail address: kanaza-h@kumamoto-u.ac.jp.

2214-0271/© 2022 Heart Rhythm Society. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Case report

A 78-year-old man was hospitalized at another hospital for congestive heart failure and was diagnosed with ATTRwt-CM as a result of $^{99}$mTc-PYP scintigraphy, myocardial biopsy, and genetic testing of transthyretin, which showed no genetic mutation. Hypertrophic cardiomyopathy, ischemic cardiomyopathy, and other secondary cardiomyopathies were excluded by cardiac MRI, coronary angiography, and other examinations and clinical findings. At the time of hospitalization at another hospital, AT had been sustained, but oral administration of 50 mg/day amiodarone, which was prescribed in a very small amount owing to concerns about exacerbation of heart failure, did not restore sinus rhythm even after discharge. The heart failure worsened despite attempted heart rate control therapy. Because AT recurred immediately after cardioversion, the patient was admitted to our hospital for catheter ablation.

On a 12-lead electrocardiogram before admission, AT with an atrial rate of 180 beats per minute and an atrioventricular (AV) conduction ratio of 3:1 was sustained (Figure 1A), while another AT with an atrial rate of 155 beats per minute and an AV conduction ratio of 1:1 was sustained at the time of admission to our hospital (Figure 1B). The wall motion of the left ventricle (LV) was reduced owing to the tachycardia, and the ejection fraction decreased to 33%. However, there was concentric hypertrophy of the LV wall, and delayed imaging showed diffuse late gadolinium enhancement in the entire LV and right ventricular wall (Figure 1C). The native T1 of the thickened interventricular septum was markedly extended to 1444 ms (D). Extracellular volume was abnormally high at 89% (E).

Figure 1  Twelve-lead electrocardiogram (ECG) of atrial tachycardia (AT) and magnetic resonance imaging. A: Twelve-lead ECG of AT before admission. B: Twelve-lead ECG of AT the time of admission to our hospital. C-E: Contrast-enhanced magnetic resonance imaging images. Late gadolinium enhancement was diffusely found in the entire thickened left ventricular wall, right ventricular wall, and left atrial wall (C). The native T1 of the thickened interventricular septum was markedly extended to 1444 ms (D). Extracellular volume was abnormally high at 89% (E).

As AT originating from the AV annulus’ was suspected, entrainment pacing was delivered from the high anterolateral RA, high posterolateral RA, high anteroseptal RA, high posteroseptal RA, low posterolateral RA, low posteroseptal RA, and high anteroseptal RA, and
CS ostium. However, although AT was entrained from all 8 sites, the EAAS was not accurately captured orthodromically, suggesting that the mechanism of AT2 was microreentry. Catheter ablation targeting the EAAS was performed using an irrigated contact force–sensing catheter (TactiCath SE, Abbott Laboratories); however, AT2 was not terminated even by the application of radiofrequency energy (RF), including around the EAAS. Then AT2 remapping was conducted; however, AT2 was also unexpectedly terminated by the contact of the HD Grid catheter with the RA wall. Therefore, further reinduction of AT was attempted, and AT1 was induced and sustained.

Because the EAAS of AT1 was also seen in the RA near the 9 o’clock position of the tricuspid valve in the LAO view (Figure 2B) and displayed a centrifugal activation pattern, the pacing of entrainment was performed from the same 7 sites of the RA and CS ostium. However, since the EAAS of AT1 was not orthodromically captured even though entrained from all sites, the RF was applied to the EAAS of AT1, resulting in the extension of the TCL and the termination of AT1. Subsequently, to evaluate the effect of catheter ablation, burst pacing from the CS was performed again, and another AT3 (TCL = 426 ms, Supplemental Figure 1) was immediately induced and sustained. However, AT3 was fragile and terminated during the mapping, and the RF application was delivered to the EAAS of AT3 within the mapping area (the RA near the 8 o’clock position of the tricuspid valve in the LAO view, Figure 2C). In addition, even though another different AT4 (TCL = 455 ms, Supplemental Figure 1) was induced by CS burst pacing, AT4 was also easily terminated by contact with the catheter again. Nevertheless, after RF application to the EAAS of AT4 within the mapping area...
region (RA appendage, Figure 2C), sustained AT was not inducible, and the ablation procedure was concluded. However, AT with an atrial rate of 110 beats per minute and an AV conduction ratio of 1:1 recurred on the second day after catheter ablation and recurred despite cardioversion. Although the intravenous administration of amiodarone (6-hour loading dose infusion of 48 mg/h followed by maintenance infusion of 25 mg/h) and landiolol were attempted, these were limited by hypotension and cardiogenic shock, requiring intravenous infusion of dobutamine and noradrenaline. For worsening acute renal and liver failure secondary to cardiogenic shock, percutaneous mechanical circulatory support (Impella; Abiomed Inc, Danvers, MA) was initiated. Owing to the restrictive nature of cardiac amyloidosis, both the tachycardia, and the negative inotropic effects of amiodarone and landiolol worsened the hemodynamics similarly. Even though cardioversion was performed several times, sinus rhythm could not be maintained and returned to AT or AF rhythm within a few days. Therefore, the second attempt at catheter ablation for AT/AF was conducted on the 85th day of hospitalization under same sedation and analgesics. As a result of mapping using the HD Grid catheter, the EAAS of tachycardia (TCL = 470 ms, Supplemental Figure 1) was observed in the CS ostium (Figure 2D) and displayed a centrifugal activation pattern. Although differential atrial overdrive pacing was performed, no ventriculoatrial linking was observed, suggesting that the tachycardia was AT (AT5). Because EAAS of AT5 was entrained but not orthodromically captured, the application of RF was delivered to the EAAS, and focal microreentrant AT5 was finally terminated by the catheter bump to the anterior CS ostium. AT6 (TCL = 721 ms, Supplemental Figure 1) was also easily induced and sustained by the burst pacing from the CS; however, the focal microreentrant AT6 originating from the high anteroseptal RA (Figure 2E) was also terminated by the catheter bump to the EAAS of AT6, and the RF application to the EAAS of AT6 was delivered. Subsequently, a voltage map was created after bilateral pulmonary vein isolation for AF (Figure 2F), but a low-voltage area of 0.05 mV or less was widespread throughout the left atrium. Furthermore, other AT episodes in which the EAAS were likely to exist at a high posterolateral RA (AT7) and low anterolateral RA (AT8) were induced (Figure 2G and 2H and Supplemental Figure 1); however, both AT episodes terminated during the mapping, and RF was applied to the EAAS of these AT episodes. Finally, although not all of the AT episodes could be treated completely and relentless AT episodes were induced by CS burst pacing, tachycardia could be stopped by pacing; therefore, the second ablation procedure was concluded, and the patient was followed up.

However, AT recurred 2 days after the session and recurred after cardioversion; therefore, a cardiac resynchronization therapy (CRT) defibrillator was implanted, and antitachycardia pacing was attempted. Nevertheless, since AT could not be terminated by antitachycardia pacing, AV node ablation was performed on the 129th day of hospitalization. As a result, heart failure could be controlled, and the patient was transferred to the referral hospital. One year later, the patient had not been readmitted to our hospital (Figure 3).

**Discussion**

Cardiac amyloidosis is often accompanied by AF and other supraventricular arrhythmias because of amyloid fibril deposits in the extracellular matrix, resulting in an increase in the left atrial pressure owing to diastolic dysfunction associated with LV wall thickening and the conduction dysfunction owing to amyloid deposits in the atrium. The multiple focal AT that occurred this time was considered reentrant
tachycardia because it can be induced and stopped by pacing, and entrained. However, the EAAS was not captured orthodromically regardless of the direction of entrainment pacing, and it seems that there were numerous slow conduction zones everywhere in the atrium. When the atrial voltage decreases owing to the progression of amyloidosis or aging, multiple focal microreentrant AT episodes may occur, which we have confirmed in 3 ATTRwt-CM cases, including this case. These patients were 78, 80, and 83 years old, and the tachycardia rate control therapy was also acceptable owing to their age. Therefore, heart failure control can be achieved by performing AV node ablation and CRT defibrillator implantation. Tan and colleagues reported that AV node ablation is also useful in advanced amyloidosis. It was considered better not to treat too many AT episodes in ATTRwt-CM multiple focal AT cases, because it is difficult to treat all AT episodes even with repeated RF application. Furthermore, in all cases, AT episodes were sustained but easily stopped by the catheter contact to the atrium wall during mapping, whereas AT episodes were not stopped easily by RF application, suggesting that AT episodes are vulnerable but insistent owing to an arrhythmogenic substrate that was widely spread throughout the atrium, which is also characteristic of multiple focal microreentrant AT episodes in ATTRwt-CM. If the presence of ATTRwt-CM is known in advance, it is better not to target for treatment inducible nonclinical AT episodes too much; in that sense, preoperative diagnosis of ATTRwt-CM is very important. Furthermore, Tafamidis treatment was also introduced in this case, but it was discontinued owing to the loss of appetite, loose stools, and weight loss. Tafamidis treatment improves the prognosis of ATTRwt-CM, meaning that it may be an optional therapy in addition to AV node ablation and CRT in ATTRwt-CM multiple focal microreentrant AT cases in the future.

Conclusion

In patients with ATTRwt-CM, complete treatment of multiple focal microreentrant AT episodes by ablation is difficult. If multiple focal microreentrant AT episodes are observed in ATTRwt-CM, it is important to consider AV node ablation without excessive treatment for AT.

Appendix

Supplementary data

Supplementary data associated with this article can be found in the online version at [typesetter will provide link].

References

1. Yamada T, Takashio S, Arima Y, et al. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan. ESC Heart Fail 2020;7:2829–2837.
2. Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 2016;133:282–290.
3. González-López E, Gagliardi C, Dominguez F, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J 2017;38:1895–1904.
4. Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016;68:1014–1020.
5. R apezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidosis: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203–1212.
6. Tan NY, Mohsin Y, Hodge DO, et al. Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 2016;27:1167–1173.
7. Yamabe H, Okumura K, Koyama J, Kanazawa H, Hoshiyama T, Ogawa H. Demonstration of anatomic reentrant circuit in verapamil-sensitive atrial tachycardia originating from the atrioventricular annulus other than the vicinity of the atrioventricular node. Am J Cardiol 2014;113:1822–1828.
8. Maruyama M, Kobayashi Y, Miyachi Y, et al. The VA relationship after differential atrial overdrive pacing: a novel tool for the diagnosis of atrial tachycardia in the electrophysiologic laboratory. J Cardiovasc Electrophysiol 2007;18:1127–1133.
9. Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol 2020;6:351–361.
10. Barbhaiya CR, Kumar S, Baldinger SH, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm 2016;13:383–390.
11. Maurer MS, Schwartz JH, Gundapueni B, et al. ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007–1016.